About Dendritics
Dendritics is a Healthcare company based in Lyon (France) founded in 2005, and was acquired by Eurobio scientific in July 2018. Monoclonal antibodies for dendritic cells are developed and marketed. The company was acqui-hired. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Reagents and Kits and Proteomics.
Company details
Dendritics is engaged in the development and marketing mouse and rat monoclonal antibodies targeting the dendritic cells and their micro-environment. In collaboration with DNAX Research Institute, the company offers B lymphocytes, elaboration of human monoclonal antibodies, and in cytokine discovery (IL-3, IL-4, IL-7, IL-10, IL-17, GM-CSF). It also markets an innovative process packaged as a transferable kit intended for multi species B cell immortalization intended for B cell repertoire analysis. It provides B cell immortalization as services on-demand.
- Headquarters Lyon, France
- Stage Acquired
- SectorsHealthcare
- Phone•••• ••••
- Website dendritics.net
- Acquired by Eurobio scientific (Jul 2018)
- Investors
- Acquired byEurobio scientific
(Jul 2018)
Investors in Dendritics
Dendritics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Eurobio scientific.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Provider of vitro diagnostic services and products | 1997 | eurobio-scientific.com | Paris, France |
Investor details for Dendritics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Dendritics
2 dated milestones of Dendritics across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Dendritics is founded.
- Exit Acquired by Eurobio scientific.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Dendritics
Complete news archive for Dendritics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Dendritics
Dendritics was founded in 2005.
Dendritics is headquartered in Lyon, France. It is registered at Lyon, Auvergne-rhone-alpes, France.
Dendritics is engaged in the development and marketing mouse and rat monoclonal antibodies targeting the dendritic cells and their micro-environment. In collaboration with DNAX Research Institute, the company offers B lymphocytes, elaboration of human monoclonal antibodies, and in cytokine discovery (IL-3, IL-4, IL-7, IL-10, IL-17, GM-CSF). It also markets an innovative process packaged as a transferable kit intended for multi species B cell immortalization intended for B cell repertoire analysis. It provides B cell immortalization as services on-demand.
Dendritics has 1 investor. Key investors include Eurobio scientific.
Yes. Dendritics was acquired by Eurobio scientific in July 2018.